Evidence map›Paper›PMID 29105958›Full record

Trial reportJournal of clinical hypertension (Greenwich, Conn.)2018

Additivity of nebivolol/valsartan single-pill combinations versus other single-pill combinations for hypertension.

Jack Ishak, Michael Rael, Henry Punzi, Alan Gradman, Lynn M Anderson, Mehul Patel, Sanjida Ali, William Ferguson, Joel Neutel

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical hypertension (Greenwich, Conn.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Effect of Amlodipine/Valsartan Versus Nebivolol/Valsartan Fixed Dose Combinations on Peripheral and Central Blood Pressure.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2018
    Trial
  3. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 2 countries.

Jack IshakEvidera, St-Laurent, QC, Canada.ORCID 0000-0002-9311-2399
Michael RaelEvidera, San Francisco, CA, USA.
Henry PunziUT Southwestern Medical Center, Dallas, TX, USA.
Alan GradmanTemple University School of Medicine, Pittsburgh, PA, USA.
Lynn M AndersonPrescott Medical Communications Group, Chicago, IL, USA.
Mehul PatelAllergan plc, Harborside Financial Center, Jersey City, NJ, USA.
Sanjida AliAllergan plc, Harborside Financial Center, Jersey City, NJ, USA.
William FergusonAllergan plc, Harborside Financial Center, Jersey City, NJ, USA.
Joel NeutelOrange County Research Center, Tustin, CA, USA.
Allergan (United States) · USEVRAZ (Canada) · CAIthaka Harbors · USOrange County Research Center · USPrescott College · USSouthwestern Medical Center · USTemple University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The single-pill combination (SPC) comprising nebivolol (5 mg), a vasodilatory β

Indexed as

HypertensionNebivololValsartanAdrenergic beta-1 Receptor AgonistsAgedAngiotensin II Type 1 Receptor BlockersAntihypertensive AgentsBlood Pressure DeterminationDose-Response Relationship, DrugDrug CombinationsDrug MonitoringDrug SynergismFemaleHumansMaleMiddle AgedAdrenergic beta-1 Receptor AgonistsAngiotensin II Type 1 Receptor BlockersAntihypertensive AgentsDrug CombinationsNebivololValsartanantihypertensive agentsdrug combinationefficacyhypertensionnebivololvalsartan

Identifiers

PMID29105958
PMCPMC5813198
OpenAlexW2767322323

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.